Novo Nordisk and Hims & Hers Forge New Path After Legal Dispute

Novo Nordisk plans to distribute its weight-loss drugs via Hims & Hers, ending a legal dispute. The move refocuses on FDA-approved GLP-1s as Novo faces a pipeline setback.

A contentious public legal battle between pharmaceutical giant Novo Nordisk and telehealth provider Hims & Hers Health appears to be shifting toward a renewed commercial partnership. The focus remains the lucrative market for GLP-1 weight-loss medications and patient access to these therapies. This reported reconciliation marks a significant strategic pivot for both companies.

From Courtroom to Collaboration

According to a Friday report from Bloomberg, Novo Nordisk is planning to distribute its branded weight-management drugs through the Hims & Hers Health digital platform. Such a deal would defuse a conflict that spanned several months, which included a public debate over "compounding"—the practice of creating mixed alternative drug formulations.

The dispute escalated sharply earlier this year. On February 9, 2026, Novo Nordisk filed a patent infringement lawsuit. This legal action came shortly after Hims & Hers launched a $49 version of a compounded semaglutide product, mimicking Novo's Wegovy. The Danish company had previously terminated an earlier cooperation in June 2025, accusing Hims & Hers of illegally marketing and distributing compounded products on a large scale.

Facing legal and regulatory pressure, Hims & Hers subsequently withdrew that product. The newly reported partnership suggests a mutual refocusing on officially approved, FDA-authorized GLP-1 medications, moving away from compounded alternatives.

Pipeline Setback Amid Fierce Competition

While navigating this partnership, Novo Nordisk is confronting challenges elsewhere. The company announced on February 23 that its drug candidate CagriSema failed to meet the primary endpoint in the phase 3 REDEFINE 4 trial. The study, which compared CagriSema to Eli Lilly's tirzepatide, did not achieve the required non-inferiority in weight loss.

In the 84-week open-label study, patients on CagriSema achieved 23.0% weight loss (based on an "if-all-adhere" analysis). Tirzepatide resulted in 25.5% weight loss. In a market where marginal efficacy differences can shift billions in revenue, this outcome is a notable development.

Securing Supply and Exploring New Benefits

To ensure long-term supply capacity, Novo Nordisk is making substantial capital investments. On March 2, the firm committed €432 million to expand a tablet manufacturing facility in Athlone, Ireland. The goal is to increase production volume for oral GLP-1 therapies, with completion scheduled in phases between late 2027 and 2028.

New research is also highlighting potential additional benefits for this class of drugs. A study published in Nature Communications on March 2 indicated that GLP-1 medications might help prevent "no-reflow" vascular complications in patients following a heart attack. This represents a possible ancillary benefit that could further enhance the medical profile of these treatments.

The mixed news flow is reflected in the share price performance. Despite a recovery over the past seven trading days, Novo Nordisk's stock remains significantly down over a twelve-month horizon (Friday closing price: €33.17). The market could receive concrete news as soon as Monday, with Bloomberg reporting that the companies may officially announce their cooperation then.